Our Pricing

Compare Acid Reflux Treatments: PPI Options UK

Published on: June 03, 2026

When you compare acid reflux treatments UK options, understanding the differences between proton pump inhibitors (PPIs) helps you make informed decisions about your digestive health. At Cured Pharmacy, our UK-registered clinical team provides transparent pricing from £9.99 and expert guidance on choosing the right PPI for your symptoms, all backed by a free three-minute online consultation with a UK prescriber.

Understanding Proton Pump Inhibitors: How PPIs Work

Proton pump inhibitors represent the most effective class of medications for managing acid reflux and gastro-oesophageal reflux disease (GORD) in the UK [1]. PPIs work by blocking the hydrogen-potassium ATPase enzyme system in gastric parietal cells, reducing stomach acid production by up to 90% within 24 hours of the first dose [1][2].

Unlike antacids that neutralise existing acid or H2 receptor antagonists that provide temporary relief, PPIs offer sustained acid suppression throughout the day. Clinical trials demonstrate that PPIs heal oesophageal erosions in approximately 80-90% of patients within eight weeks, making them the gold standard for moderate to severe acid reflux [2][3].

The MHRA licenses seven different PPI molecules in the UK, each with distinct pharmacokinetic profiles affecting onset time, duration of action, and drug interactions. Understanding these differences helps UK prescribers match the right PPI to individual patient needs, symptoms patterns, and concurrent medications.

Omeprazole vs Lansoprazole: First-Line PPI Comparison

Omeprazole and lansoprazole remain the most prescribed PPIs in the UK, with decades of safety data supporting their efficacy [3]. Omeprazole, the first PPI introduced in 1989, typically costs from £9.99 for generic formulations at Cured Pharmacy, whilst lansoprazole offers similar effectiveness from £9.99.

Both medications achieve peak plasma concentrations within 1.5 to 3.5 hours, but lansoprazole demonstrates slightly faster acid suppression in some patients [4]. Meta-analyses show comparable healing rates for oesophagitis, with 12-week remission rates exceeding 85% for both molecules at standard doses [3][4].

The choice between these two often depends on individual response rather than superiority of one over the other. Some patients experience better symptom control with lansoprazole's faster onset, whilst others prefer omeprazole's extensive drug interaction data and lower cost. Both require clinical assessment by a UK prescriber, who will consider your medical history, concurrent medications, and symptom severity.

Dosing Flexibility and Formulation Options

Omeprazole is available in 10mg and 20mg capsules at Cured Pharmacy, allowing dose titration based on symptom severity. Lansoprazole comes in 15mg and 30mg strengths, with the higher dose typically reserved for more severe GORD or healing of erosive oesophagitis. Both medications should be taken 30-60 minutes before breakfast for optimal acid suppression throughout the day.

Esomeprazole and Pantoprazole: Next-Generation PPIs

Esomeprazole, the S-isomer of omeprazole, offers enhanced pharmacokinetic properties with more predictable acid control across diverse patient populations [5]. Available from £9.99 at Cured Pharmacy, esomeprazole achieves higher plasma concentrations than racemic omeprazole at equivalent doses, potentially benefiting patients who haven't responded adequately to first-line PPIs [5].

Pantoprazole, priced from £9.99, distinguishes itself through minimal cytochrome P450 interactions, making it particularly suitable for patients taking multiple medications [6]. Clinical trials show pantoprazole maintains stable acid suppression regardless of CYP2C19 genetic polymorphisms that affect other PPI metabolism, ensuring consistent efficacy across ethnic populations [6].

Head-to-head trials demonstrate that esomeprazole 40mg provides faster symptom relief in the first week compared to other PPIs, with 92% of patients achieving heartburn resolution within eight weeks [5]. Pantoprazole's gastro-resistant coating ensures the active ingredient bypasses stomach acid intact, providing reliable symptom control particularly for patients with unpredictable eating patterns.

Choosing Between Second-Generation PPIs

UK prescribers typically consider esomeprazole for patients requiring rapid symptom control or those with documented erosive oesophagitis. Pantoprazole suits patients with complex medication regimens or those who've experienced drug interactions with other PPIs. Both options require online clinical assessment to ensure appropriate prescribing based on your individual circumstances.

Brand vs Generic PPIs: Losec, Nexium, and Zoton Fastabs

Branded PPIs like Losec (omeprazole), Nexium (esomeprazole), and Zoton Fastabs (lansoprazole) contain the same active ingredients as generic versions but may offer different formulations or delivery systems. Losec capsules, available from £9.99 at Cured Pharmacy, represent the original omeprazole formulation with extensive clinical heritage.

Nexium tablets 40mg, priced from £9.99, provide the branded esomeprazole option for patients who prefer the manufacturer's original formulation. Some patients report subjective differences in tolerability between branded and generic versions, though bioequivalence studies confirm comparable efficacy [7].

Zoton Fastabs, available from £9.99, offer a unique orodispersible formulation that dissolves on the tongue without water. This makes them particularly suitable for patients with swallowing difficulties, those requiring nasogastric administration, or individuals who struggle with capsule formulations. The Fastab technology delivers lansoprazole 30mg with the same bioavailability as conventional capsules whilst improving convenience [7].

When to Consider Branded Options

Whilst generic PPIs offer excellent value, branded options may benefit patients who've experienced inconsistent responses to different generic manufacturers, those requiring specific formulations like orodispersible tablets, or individuals who prefer the reassurance of original branded medications. Your UK prescriber will discuss whether branded or generic options best suit your clinical needs during your online consultation.

Over-the-Counter vs Prescription-Strength PPIs

Pyrocalm 20mg, available from £9.99 at Cured Pharmacy, represents an over-the-counter omeprazole option licensed for short-term management of reflux symptoms in adults. OTC PPIs are restricted to 14-day treatment courses and require pharmacy supervision to ensure appropriate use [8].

Prescription-strength PPIs allow longer treatment duration, higher doses, and ongoing monitoring by UK prescribers. Whilst OTC options suit occasional heartburn sufferers, patients with frequent symptoms (more than twice weekly), nocturnal reflux, or suspected oesophagitis require prescription assessment to exclude serious underlying conditions and ensure appropriate long-term management [8].

The distinction between OTC and prescription PPIs isn't just about strength—it's about clinical oversight. Persistent acid reflux may indicate GORD requiring investigation, Barrett's oesophagus needing surveillance, or H. pylori infection warranting eradication therapy. Our UK clinical team assesses these factors during your online consultation to ensure you receive the most appropriate treatment pathway.

Choosing the Right PPI: Clinical Factors and Cost Considerations

When comparing acid reflux treatments, UK prescribers consider symptom severity, frequency, previous treatment responses, concurrent medications, and cost. Generic omeprazole from £9.99 offers excellent first-line value, whilst alternative PPIs provide options if initial treatment proves inadequate.

Patients with erosive oesophagitis typically require 8-12 weeks of full-dose PPI therapy, whilst those with non-erosive reflux disease may achieve symptom control with lower doses or intermittent treatment [2][3]. Some individuals become 'PPI non-responders', requiring dose escalation, twice-daily dosing, or switching to alternative PPIs with different pharmacokinetic profiles.

At Cured Pharmacy, our transparent pricing model shows costs before consultation, and our UK prescribers select treatments based on clinical appropriateness rather than price. All prescription PPIs require online assessment to ensure safe prescribing, appropriate dose selection, and monitoring for potential long-term effects. Starting your free consultation takes under three minutes, with discreet delivery throughout the UK.

Long-Term PPI Use and Monitoring

Extended PPI therapy beyond 12 months requires periodic review to assess ongoing need, consider dose reduction, and monitor for potential effects on nutrient absorption. UK prescribers recommend the lowest effective dose for symptom control, with regular attempts at dose reduction or discontinuation where clinically appropriate. Your online consultation includes discussion of treatment duration and follow-up recommendations.

Scientific References

1. Shin, J. M., & Sachs, G. (2008). Pharmacology of proton pump inhibitors. Current Gastroenterology Reports, 10(6), 528-534. https://doi.org/10.1007/s11894-008-0098-4 [accessed 13 August 2026]
2. Kahrilas, P. J., et al. (2008). American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology, 135(4), 1383-1391. https://doi.org/10.1053/j.gastro.2008.08.045 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2014). Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management (CG184). NICE. https://www.nice.org.uk/guidance/cg184 [accessed 13 August 2026]
4. Kirchheiner, J., et al. (2009). Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical Pharmacology & Therapeutics, 85(6), 607-617. https://doi.org/10.1038/clpt.2009.27 [accessed 13 August 2026]
5. Kahrilas, P. J., et al. (2000). Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Alimentary Pharmacology & Therapeutics, 14(10), 1249-1258. https://doi.org/10.1046/j.1365-2036.2000.00856.x [accessed 13 August 2026]
6. Blume, H., et al. (2006). Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Safety, 29(9), 769-784. https://doi.org/10.2165/00002018-200629090-00002 [accessed 13 August 2026]
7. Medicines and Healthcare products Regulatory Agency. (2019). Proton pump inhibitors in the UK: guidance on prescribing and monitoring. MHRA Drug Safety Update. https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
8. Raghunath, A. S., et al. (2005). A randomized, double-blind, placebo-controlled study to assess the efficacy of omeprazole for the long-term relief of heartburn. International Journal of Clinical Practice, 59(12), 1425-1432. https://doi.org/10.1111/j.1742-1241.2005.00645.x [accessed 13 August 2026]
9. NHS. (2026). Heartburn and acid reflux. https://www.nhs.uk/conditions/heartburn-and-acid-reflux/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.